Abstract 11P
Background
Breast cancer is the second leading cause of cancer deaths in women worldwide. Early detection of breast cancer has been demonstrated to improve patients' treatment outcomes and survival. Liquid biopsy based on detecting DNA shed by breast tumors into the circulation, known as circulating tumor DNA (ctDNA), has emerged as a promising non-invasive approach. However, differentiating benign breast lumps from malignant tumors remains a challenge in current clinical practice, and inaccurate detection may result in unnecessary invasive procedures.
Methods
To address this challenge, we employed a multimodal analysis approach, namely SPOT-MAS (Screen for the Presence of Tumor by DNA Methylation and Size) to profile alterations in methylation and fragment length patterns of cell free DNA (cfDNA) from 133 breast cancer patients and 59 patients with benign breast lumps comprising cysts and fibroadenomas.
Results
We identified multiple distinct end motifs, differential methylation and fragment length patterns across 22 chromosomes, which were further exploited as input features to build machine learning models to discriminate early-stage breast cancer patients from patients with benign lesions. The models achieved an area under the curve of 0.87 (95% CI: 0.79 – 0.94) and a sensitivity of 64.1% at 90% specificity in detecting patients with malignant tumors.
Conclusions
Therefore, our findings demonstrated that cancer-specific methylation and fragmentomic patterns in plasma cfDNA could serve as novel biomarkers for accurately differentiating malignant breast cancer patients from those with benign lesions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute and Gene Solutions Joint Stock Company, Vietnam.
Funding
Gene Solutions Joint Stock Company.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract